Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New lens combo may cut annoying halos after cataract surgery

NCT ID NCT07295119

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two different lens approaches for cataract surgery: one group got two different extended-depth-of-focus lenses (one in each eye), and the other got the same trifocal lens in both eyes. The goal was to see which caused fewer halos and better vision. 36 adults having cataract surgery in both eyes took part. Researchers measured halo size and visual sharpness three months after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intraocular lenses (IOLs)
What this could lead to
If successful, this study could help doctors choose the best lens type to reduce glare and halos after cataract surgery, improving patient satisfaction.
What could go wrong
This is a small, completed study with only 36 participants. Results may not apply to everyone, and any lens can still cause visual disturbances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Apr 2023

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Diagnosis of age-related cataract in both eyes requiring bilateral cataract surgery. * Corneal astigmatism 0.50 diopters or less in each eye. * No other media opacities except cataract. * Regular corneal shape without abnormal curvature or high-order aberrations on topography/aberrometry. * Intraocular lens spherical power between +10.00 and +30.00 diopters according to biometry and IOL calculation. * Willing and able to undergo surgery in the second eye within 7 days of the first-eye surgery. * Willing and able to attend all scheduled follow-up visits, including the 3-month visit. * Able to understand the study information and provide written informed consent. Exclusion Criteria: * Any prior ocular surgery in either eye. * Any concomitant ocular disease that could affect visual outcomes (for example glaucoma, retinal disease, significant macular pathology, corneal dystrophy or degeneration, keratoconus, significant dry eye not controlled with treatment). * Clinically significant irregular astigmatism or corneal scarring. * Any intraoperative complication during cataract surgery that could compromise IOL position or visual outcome (such as posterior capsule rupture, zonular dialysis); such eyes will be excluded from the analysis set. * Significant posterior capsule opacification before the 3-month outcome visit requiring YAG capsulotomy. * Systemic disease or neurological condition that, in the investigator's opinion, may affect visual function, ability to complete testing (for example halometry, questionnaires), or study participation. * Cognitive impairment or psychiatric condition that precludes giving informed consent or complying with study procedures. * Participation in another interventional clinical study that could interfere with outcomes of this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AOUI Verona

    Verona, Verona, 37134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.